Research
We connect liquid biopsy technology, lymphoma biology, and experimental research to investigate how disease can be characterized and monitored.
Research direction 01
Lymphoma biology & heterogeneity
Which molecular features distinguish lymphoma subtypes?
Molecular profiling
We combine genomic profiling and computational analysis to investigate molecular heterogeneity and the biological differences between lymphomas.
Our work connects molecular profiles with questions about lymphoma classification and behavior. Noninvasive profiling offers a way to investigate this diversity and follow molecular changes over time.
Related publications
Research direction 02
Liquid biopsy & molecular monitoring
How can tumor-derived DNA help us monitor lymphoma more precisely?
Circulating tumor DNA
We develop sensitive circulating tumor DNA approaches to study lymphoma through blood samples and assess molecular changes during treatment.
Circulating tumor DNA (ctDNA) is tumor-derived DNA found in blood. Our research investigates how this information can support disease characterization, response assessment, and the detection of minimal residual disease.
Related publications
Research direction 03
Treatment resistance & clonal evolution
How does lymphoma evolve during therapy, and what contributes to resistance?
Clonal evolution and resistance
We study clonal evolution and resistance mechanisms using genomic analysis and pre-clinical functional models.
By investigating how lymphoma changes over time, we aim to understand the biological mechanisms associated with treatment resistance. Experimental models complement molecular observations and help us explore clinically relevant questions.
Related publications
Research terminology
What is a liquid biopsy?
A liquid biopsy examines material in a body fluid, such as blood, to obtain information about disease. Our research focuses on tumor-derived DNA.
What is circulating tumor DNA (ctDNA)?
Circulating tumor DNA is DNA released by tumor cells that can be found in blood. We study its molecular features and changes over time.
What is minimal residual disease?
Minimal residual disease refers to small amounts of disease remaining after treatment. We investigate molecular approaches to its detection in lymphoma.